Current limitations of antiretroviral therapy are driving interest in novel HIV eradication strategies. Extracellular vesicles (EVs) are nano-sized membrane vesicles involved in cell signaling which have shown promise as engineerable therapeutic agents. We used surface display technology to engineer HIV-targeting EVs (HTEVs) that block HIV infection and target infected cells.
EVs were isolated from healthy donor plasma using polymer-based precipitation and column purification. EVs were decorated with single-chain variable fragment (scFv)-C1C2 fusion proteins targeting the HIV envelope protein. Surface-engineered EVs and HIV particles were fluorescently labeled and incubation reactions were visualized in dual-color channel and single-particle tracking analysis using a Nanoimager (ONI). Decorated EVs were incubated for two hours with a GFP-reporter HIV strain at 1:1, 2:1, and 4:1 ratios. Jurkat E6.1 cells and primary human CD4+ T cells were infected via spinoculation. Reporter virus was incubated with no EVs, undecorated EVs, or anti-PD-1 scFv–decorated EVs as negative controls. Jurkat 2D10 cells were induced with PMA/TSA to reactivate latent HIVNL4-3-Dgag/pol-GFP reporter virus and then were treated with Texas red-labeled control or anti-HIV-C1C2 fusion proteins decorated EVs. After 24h, cells were analyzed by flow cytometry. TZM-bl cells were in vitro infected with HIVNL4-3P2A-Nef and two days later were treated with labeled EVs, decorated with C1C2 (control) or anti-HIV-C1C2 proteins. Internalization of decorated EVs was assessed after 18h incubation using fluorescence microscopy.
Tracking data revealed that HTEVs clustered and moved in tandem with HIV virions, in contrast to negative controls which did not form clusters and tracked independently of virions. HTEVs significantly inhibited HIV infection in Jurkat E6.1 cells (n=3) and CD4+ T cells (n=5 donors) with respect to negative controls (p<0.05, paired t-test). HTEVs efficiently directed EVs into latently-infected, reactivated T lymphoid cells and in vitro HIV-1-infected TZM-bl cells.
HTEVs suppress HIV infection and selectively target infected cells ex vivo following latency reversal. HTEVs may facilitate the clearance of the latent HIV reservoir by delivering cytotoxic cargo specifically to infected cells.